132 related articles for article (PubMed ID: 36006635)
21. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.
Ng OT; Marimuthu K; Koh V; Pang J; Linn KZ; Sun J; De Wang L; Chia WN; Tiu C; Chan M; Ling LM; Vasoo S; Abdad MY; Chia PY; Lee TH; Lin RJ; Sadarangani SP; Chen MI; Said Z; Kurupatham L; Pung R; Wang LF; Cook AR; Leo YS; Lee VJ
Lancet Infect Dis; 2021 Mar; 21(3):333-343. PubMed ID: 33152271
[TBL] [Abstract][Full Text] [Related]
22. Association of SARS-CoV-2 Infection With Psychological Distress, Psychotropic Prescribing, Fatigue, and Sleep Problems Among UK Primary Care Patients.
Abel KM; Carr MJ; Ashcroft DM; Chalder T; Chew-Graham CA; Hope H; Kapur N; McManus S; Steeg S; Webb RT; Pierce M
JAMA Netw Open; 2021 Nov; 4(11):e2134803. PubMed ID: 34783824
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
24. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
[TBL] [Abstract][Full Text] [Related]
25. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.
Zinszer K; McKinnon B; Bourque N; Pierce L; Saucier A; Otis A; Cheriet I; Papenburg J; Hamelin MÈ; Charland K; Carbonneau J; Zahreddine M; Savard A; Fortin G; Apostolatos A; Haley N; Ratté N; Laurin I; Nguyen CT; Conrod P; Boivin G; De Serres G; Quach C
JAMA Netw Open; 2021 Nov; 4(11):e2135975. PubMed ID: 34812845
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults.
Li Y; Tong CH; Bare LA; Devlin JJ
JAMA Netw Open; 2021 May; 4(5):e2111634. PubMed ID: 34009346
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Face-Touching Behaviors Before and During the Coronavirus Disease 2019 Pandemic.
Chen YJ; Qin G; Chen J; Xu JL; Feng DY; Wu XY; Li X
JAMA Netw Open; 2020 Jul; 3(7):e2016924. PubMed ID: 32725247
[TBL] [Abstract][Full Text] [Related]
28. Prospective surveillance study in a 1,400-bed university hospital: COVID-19 exposure at home was the main risk factor for SARS-CoV-2 point seroprevalence among hospital staff.
Bahrs C; Kimmig A; Weis S; Ankert J; Hagel S; Maschmann J; Stallmach A; Steiner A; Bauer M; Behringer W; Baier M; Kesselmeier M; Richert C; Zepf F; Walter M; Scherag A; Kiehntopf M; Löffler B; Pletz MW
Transbound Emerg Dis; 2022 Mar; 69(2):720-730. PubMed ID: 33605549
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of ongoing or previous SARS-CoV-2 infection among dental personnel - the Swedish experience.
Fredriksson L; Cederlund A; Murray M; Jansson L; Skott P
Acta Odontol Scand; 2023 Mar; 81(2):119-123. PubMed ID: 35771959
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study.
Eriksen ARR; Fogh K; Hasselbalch RB; Bundgaard H; Nielsen SD; Jørgensen CS; Scharff BFSS; Erikstrup C; Sækmose SG; Holm DK; Aagaard B; Kristensen JH; Bødker CA; Norsk JB; Nielsen PB; Østergaard L; Ellermann-Eriksen S; Andersen B; Nielsen H; Johansen IS; Wiese L; Simonsen L; K Fischer T; Folke F; Lippert F; Ostrowski SR; Ethelberg S; Koch A; Vangsted AM; Krause T; Fomsgaard A; Nielsen C; Ullum H; Skov R; Iversen K
BMC Public Health; 2022 Jun; 22(1):1261. PubMed ID: 35761270
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection.
Lewis N; Chambers LC; Chu HT; Fortnam T; De Vito R; Gargano LM; Chan PA; McDonald J; Hogan JW
JAMA Netw Open; 2022 Jul; 5(7):e2223917. PubMed ID: 35895058
[TBL] [Abstract][Full Text] [Related]
32. Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network - 13 Academic Medical Centers, April-June 2020.
Self WH; Tenforde MW; Stubblefield WB; Feldstein LR; Steingrub JS; Shapiro NI; Ginde AA; Prekker ME; Brown SM; Peltan ID; Gong MN; Aboodi MS; Khan A; Exline MC; Files DC; Gibbs KW; Lindsell CJ; Rice TW; Jones ID; Halasa N; Talbot HK; Grijalva CG; Casey JD; Hager DN; Qadir N; Henning DJ; Coughlin MM; Schiffer J; Semenova V; Li H; Thornburg NJ; Patel MM; ;
MMWR Morb Mortal Wkly Rep; 2020 Sep; 69(35):1221-1226. PubMed ID: 32881855
[TBL] [Abstract][Full Text] [Related]
33. Seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection among Veterans Affairs healthcare system employees suggests higher risk of infection when exposed to SARS-CoV-2 outside the work environment.
Dimcheff DE; Schildhouse RJ; Hausman MS; Vincent BM; Markovitz E; Chensue SW; Deng J; McLeod M; Hagan D; Russell J; Bradley SF
Infect Control Hosp Epidemiol; 2021 Apr; 42(4):392-398. PubMed ID: 32962771
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.
Peremiquel-Trillas P; Saura-Lázaro A; Benavente-Moreno Y; Casabonne D; Loureiro E; Cabrera S; Duran A; Garrote L; Brao I; Trelis J; Galán M; Soler F; Julià J; Cortasa D; Domínguez MÁ; Albasanz-Puig A; Gudiol C; Ramírez-Tarruella D; Muniesa J; Rivas JP; Muñoz-Montplet C; Sedano A; Plans À; Calvo-Cerrada B; Calle C; Clopés A; Carnicer-Pont D; Alemany L; Fernández E
BMJ Open; 2022 Apr; 12(4):e056637. PubMed ID: 35450905
[TBL] [Abstract][Full Text] [Related]
35. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
[TBL] [Abstract][Full Text] [Related]
36. Acceptability of restrictions in the COVID-19 pandemic: a population-based survey in Denmark and Sweden.
Nilsen P; Seing I; Sekhon M; Kallemose T; Tjørnhøj-Thomsen T; Stefánsdóttir NT; Vrangbæk K; Andersen O; Kirk JW
Front Public Health; 2023; 11():988882. PubMed ID: 37601192
[TBL] [Abstract][Full Text] [Related]
37. Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan: A cross-sectional study.
Nishida T; Iwahashi H; Yamauchi K; Kinoshita N; Okauchi Y; Suzuki N; Inada M; Abe K
Medicine (Baltimore); 2021 Jun; 100(25):e26433. PubMed ID: 34160433
[TBL] [Abstract][Full Text] [Related]
38. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
40. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
